Contents
Issue 135 • October 2023
In association with
In Depth
How pharma wants to break the efficacy ceiling in IBD
Subcutaneous drugs grant a new lease on life to checkpoint inhibitors
Hope for the UK clinical trial landscape but it requires a lot of work
Novo Nordisk’s Wegovy to start being supplied by NHS in England
Minimal impact expected for initial drugs under Medicare price negotiation
Q&A: Human touch remains critical for the patient experience in trials